Earnings Feed
Start Free
Nexvet Biopharma plc·4

Jul 1, 8:20 PM ET

Nexvet Biopharma plc 4

4 · Nexvet Biopharma plc · Filed Jul 1, 2016

Insider Transaction Report

Form 4
Period: 2016-07-01
Nexvet Biopharma plcNVET
Heffernan Mark
Chief Executive Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2016-07-01$0.13/sh+4,833$604→ 24,167 total
  • Exercise/Conversion

    Restricted Share Units

    2016-07-01−25,000→ 75,000 total
    Exercise: $0.13Exp: 2020-07-01→ Ordinary Shares (25,000 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2016-07-01$0.13/sh+25,000$3,125→ 49,167 total
  • Exercise/Conversion

    Option to Purchase Shares

    2016-07-01−4,833→ 4,833 total
    Exercise: $0.13Exp: 2019-07-01→ Ordinary Shares (4,833 underlying)
Holdings

  • Ordinary Shares

    (indirect: By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>)
    243,587
Footnotes (4)
  • [F1]The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
  • [F2]The remaining 4,833 options to purchase shares will vest and become exercisable on 7/1/17.
  • [F3]Previously reported as indirectly held.
  • [F4]25,000 of the Restricted Share Units shall vest and become convertible on each of 7/1/17, 7/1/18 and 7/1/19, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT